Evidence map›Paper›PMID 41281442›Full record

ArticleJHEP reports : innovation in hepatology2025

Platelet protease nexin-1 limits fibrinolysis in patients with cirrhosis.

Alix Riescher-Tuczkiewicz, Stéphane Loyau, Laurence Venisse, Marion Tanguy, Antoine Wawrzyniak, Emmanuelle de Raucourt, Louise Biquard, Audrey Payancé, Julien Bissonnette, François Durand and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alix Riescher-TuczkiewiczUniversité Paris Cité, Inserm, Centre de Recherche sur l'inflammation, UMR 1149, Paris, France.
Stéphane LoyauINSERM, UMR_S 1148-Laboratory for Vascular Translational Science, Université Paris Cité, Paris, France.
Laurence VenisseINSERM, UMR_S 1148-Laboratory for Vascular Translational Science, Université Paris Cité, Paris, France.
Marion TanguyUniversité Paris Cité, Inserm, Centre de Recherche sur l'inflammation, UMR 1149, Paris, France.
Antoine WawrzyniakUniversité Paris Cité, Inserm, Centre de Recherche sur l'inflammation, UMR 1149, Paris, France.
Emmanuelle de RaucourtService d'hématologie Biologique, Hôpital Beaujon, Clichy, France.
Louise BiquardUniversité Paris Cité, Inserm, Centre de Recherche sur l'inflammation, UMR 1149, Paris, France.
Audrey PayancéAP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Julien BissonnetteAP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
François DurandAP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.
Véronique ArocasINSERM, UMR_S 1148-Laboratory for Vascular Translational Science, Université Paris Cité, Paris, France.
Marie-Christine BoutonINSERM, UMR_S 1148-Laboratory for Vascular Translational Science, Université Paris Cité, Paris, France.
Yacine BoulaftaliINSERM, UMR_S 1148-Laboratory for Vascular Translational Science, Université Paris Cité, Paris, France.
Pierre-Emmanuel RautouUniversité Paris Cité, Inserm, Centre de Recherche sur l'inflammation, UMR 1149, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: The role of protease nexin 1 (PN-1), a serine protease inhibitor that regulates both coagulation and fibrinolysis, is unknown in patients with cirrhosis. This study aimed to provide a comprehensive assessment of the role of PN-1 in cirrhosis. Methods: Plasma PN-1 concentration in 212 patients with advanced chronic liver disease and 30 healthy individuals was measured by ELISA. The role of PN-1 was investigated using thrombin generation assay, rotational thromboelastometry, and clot lysis assay in platelet-rich plasma and platelet-free plasma from 10 patients with stable decompensated cirrhosis and 10 healthy individuals. Results: Plasma PN-1 concentration was higher in patients with advanced chronic liver disease than in healthy individuals (0.21 Conclusions: Platelet-derived PN-1 was found to markedly limit fibrinolysis in decompensated cirrhosis, although its impact on coagulation appeared minimal. Although elevated plasma PN-1 concentrations were observed in patients with advanced chronic liver disease, they did not contribute to hemostasis regulation. Overall, PN-1 should be added to the list of hemostasis factors that are dysregulated in cirrhosis. Impact and implications: The role of PN-1, a serpin that regulates both coagulation and fibrinolysis, is unknown in cirrhosis. PN-1 appears as an important regulator of fibrinolysis in patients with cirrhosis. The role of PN-1 (and platelets more broadly) should be taken into account when assessing fibrinolysis in patients with cirrhosis.

Indexed as

CoagulationHemostasisLiver diseaseRotational thromboelastometrySerpinE2Thrombin generation assayThrombosis

Identifiers

PMID41281442
PMCPMC12639314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.